Trial Profile
An Observational, Longitudinal Study to Evaluate and Monitor Physical Performance of Adults Treated With Asfotase Alfa for Pediatric-Onset Hypophosphatasia
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Nov 2023
Price :
$35
*
At a glance
- Drugs Asfotase alfa (Primary)
- Indications Hypophosphatasia
- Focus Therapeutic Use
- Acronyms EmPATHY
- 11 Jul 2022 Status changed from recruiting to completed.
- 01 Dec 2021 Results (n=21) assessing bone turnover and mineral metabolism in adult patients with hypophosphatasia published in the Osteoporosis International
- 06 Oct 2020 Planned End Date changed from 1 Sep 2020 to 1 May 2022.